[go: up one dir, main page]

FR3061305B1 - Methode de diagnostic des qualites esthetiques de la peau - Google Patents

Methode de diagnostic des qualites esthetiques de la peau Download PDF

Info

Publication number
FR3061305B1
FR3061305B1 FR1663364A FR1663364A FR3061305B1 FR 3061305 B1 FR3061305 B1 FR 3061305B1 FR 1663364 A FR1663364 A FR 1663364A FR 1663364 A FR1663364 A FR 1663364A FR 3061305 B1 FR3061305 B1 FR 3061305B1
Authority
FR
France
Prior art keywords
skin
diagnosing
aesthetic qualities
relates
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1663364A
Other languages
English (en)
Other versions
FR3061305A1 (fr
Inventor
Sandra Kanani
Virginie Piffaut
Aude Foucher
Mark Donovan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LOreal SA
Original Assignee
LOreal SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR1663364A priority Critical patent/FR3061305B1/fr
Application filed by LOreal SA filed Critical LOreal SA
Priority to PCT/EP2017/084547 priority patent/WO2018115517A1/fr
Priority to EP17832238.4A priority patent/EP3559671B1/fr
Priority to US16/468,073 priority patent/US12326456B2/en
Priority to ES17832238T priority patent/ES2974622T3/es
Priority to JP2019534129A priority patent/JP6949964B2/ja
Publication of FR3061305A1 publication Critical patent/FR3061305A1/fr
Application granted granted Critical
Publication of FR3061305B1 publication Critical patent/FR3061305B1/fr
Priority to JP2021110021A priority patent/JP2021166536A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6881—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from skin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/44—Detecting, measuring or recording for evaluating the integumentary system, e.g. skin, hair or nails
    • A61B5/441—Skin evaluation, e.g. for skin disorder diagnosis
    • A61B5/442—Evaluating skin mechanical properties, e.g. elasticity, hardness, texture, wrinkle assessment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/148—Screening for cosmetic compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Cosmetics (AREA)

Abstract

La présente invention concerne une méthode de diagnostic d'une dégradation des qualités esthétiques de la peau, basée sur mesure du niveau d'expression du gène codant la FLG2. La présente invention porte également sur une méthode de traitement cosmétique de la peau. La présente invention concerne également une méthode d'identification de composé de réduction et/ou le ralentissement de la dégradation de la qualité esthétique de la peau ainsi qu'un kit.
FR1663364A 2016-12-23 2016-12-23 Methode de diagnostic des qualites esthetiques de la peau Active FR3061305B1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
FR1663364A FR3061305B1 (fr) 2016-12-23 2016-12-23 Methode de diagnostic des qualites esthetiques de la peau
EP17832238.4A EP3559671B1 (fr) 2016-12-23 2017-12-22 Procédé de diagnostic des qualités esthétiques de la peau
US16/468,073 US12326456B2 (en) 2016-12-23 2017-12-22 Method of diagnosis of the aesthetic qualities of the skin
ES17832238T ES2974622T3 (es) 2016-12-23 2017-12-22 Procedimiento de diagnóstico de las cualidades estéticas de la piel
PCT/EP2017/084547 WO2018115517A1 (fr) 2016-12-23 2017-12-22 Procédé de diagnostic des qualités esthétiques de la peau
JP2019534129A JP6949964B2 (ja) 2016-12-23 2017-12-22 皮膚の審美性の診断方法
JP2021110021A JP2021166536A (ja) 2016-12-23 2021-07-01 皮膚の審美性の診断方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1663364A FR3061305B1 (fr) 2016-12-23 2016-12-23 Methode de diagnostic des qualites esthetiques de la peau
FR1663364 2016-12-23

Publications (2)

Publication Number Publication Date
FR3061305A1 FR3061305A1 (fr) 2018-06-29
FR3061305B1 true FR3061305B1 (fr) 2021-02-12

Family

ID=58779114

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1663364A Active FR3061305B1 (fr) 2016-12-23 2016-12-23 Methode de diagnostic des qualites esthetiques de la peau

Country Status (6)

Country Link
US (1) US12326456B2 (fr)
EP (1) EP3559671B1 (fr)
JP (2) JP6949964B2 (fr)
ES (1) ES2974622T3 (fr)
FR (1) FR3061305B1 (fr)
WO (1) WO2018115517A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3061305B1 (fr) * 2016-12-23 2021-02-12 Oreal Methode de diagnostic des qualites esthetiques de la peau
US11127176B2 (en) * 2019-01-31 2021-09-21 L'oreal Systems and methods for visualizing future skin trends based on biomarker analysis
US11741523B2 (en) 2019-07-31 2023-08-29 L'oreal Personalized skincare recommendations based on biomarker analysis
US11501356B2 (en) 2019-07-31 2022-11-15 L'oreal Systems and methods for generating personalized skincare formulations based on biomarker analysis
FR3100451B1 (fr) * 2019-09-05 2021-09-17 Oreal Méthode de diagnostic de peaux sèches
FR3117599B1 (fr) * 2020-12-16 2024-11-29 Oreal Méthode de pronostic et/ou de diagnostic d’un état pelliculaire du cuir chevelu

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2940976B1 (fr) 2009-01-13 2017-11-03 Oreal Utilisation a des fins de criblage d'actifs anti-ages de formes solubles de la proteine de type desmogleine i
JP2011085491A (ja) 2009-10-15 2011-04-28 Iwate Univ カスパーゼの分析方法
DE102009046128A1 (de) * 2009-10-29 2010-08-05 Henkel Ag & Co. Kgaa Nicht-invasives Screeningverfahren für Wirkstoffe gegen Hautalterung
KR100961874B1 (ko) 2010-04-05 2010-06-09 주식회사 나노엔텍 외부동력 없이 유체가 이동하는 유체분석용 칩
KR101618950B1 (ko) * 2013-04-12 2016-05-09 동국대학교 산학협력단 피부 자극 물질 스크리닝용 조성물 및 이를 이용한 피부 자극 물질의 스크리닝 방법
JP6199592B2 (ja) 2013-04-15 2017-09-20 株式会社 資生堂 分析方法
KR101507234B1 (ko) 2013-07-17 2015-03-31 로레알 생분자 추출기 및 생분자 추출방법
DK3132053T3 (da) * 2014-04-15 2020-12-14 Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Gesundheit & Umwelt Gmbh Differentialdiagnose af eksem og psoriasis
FR3061305B1 (fr) * 2016-12-23 2021-02-12 Oreal Methode de diagnostic des qualites esthetiques de la peau

Also Published As

Publication number Publication date
FR3061305A1 (fr) 2018-06-29
EP3559671A1 (fr) 2019-10-30
WO2018115517A1 (fr) 2018-06-28
JP2021166536A (ja) 2021-10-21
EP3559671B1 (fr) 2024-02-07
JP2020501587A (ja) 2020-01-23
JP6949964B2 (ja) 2021-10-13
ES2974622T3 (es) 2024-06-28
US12326456B2 (en) 2025-06-10
US20200072851A1 (en) 2020-03-05
EP3559671C0 (fr) 2024-02-07

Similar Documents

Publication Publication Date Title
FR3061305B1 (fr) Methode de diagnostic des qualites esthetiques de la peau
FR3060755B1 (fr) Methode de diagnostic d'une peau presentant des signes de secheresse
MX388989B (es) Biomarcadores basados en sangre para diagnosticar enfermedad de arteria coronaria ateroesclerótica.
EA201890724A1 (ru) Способы диагностики и оценки неалкогольного стеатогепатита
PH12021551482A1 (en) AMYLOID PRECURSOR PROTEIN (APP) RNAi AGENT COMPOSITIONS AND METHODS OF USE THEREOF
EP4321866A3 (fr) Gdf-15 utilisé comme marqueur diagnostique pour prédire le résultat clinique d'un traitement avec des bloqueurs de points de contrôle immunitaires
MA41251B1 (fr) Dérivés de thiéno[2,3-c]pyrrol-4-one comme inhibiteurs erk
EA201492284A1 (ru) Применение маркеров в диагностике и лечении рака предстательной железы
MX341840B (es) Biomarcadores de microarn indicativos de la enfermedad de alzheimer.
MX339709B (es) Antagonistas de wnt y metodos de tratamiento y analisis.
WO2015094995A3 (fr) Biomarqueurs de signature génique de réponse tumorale à des antagonistes de pd-1
WO2017066712A3 (fr) Modulateurs de maladie de télomères
MX377026B (es) Biomarcadores para la progresión de enfermedades en melanoma.
EA201792447A1 (ru) Способы и композиции для диагностики и лечения заболеваний у пациентов, имеющих повышенные уровни cxcl9 и других биомаркеров
MA35456B1 (fr) Procède de traitement fongicide et/ou bactéricide de souches résistantes au moyen d'huile(s) essentielle(s)
WO2021067850A3 (fr) Méthodes de détection d'arncirc
WO2017066796A3 (fr) Modulateurs de maladies impliquant des télomères
WO2012167086A3 (fr) Méthodes de diagnostic et de traitement d'une sclérose latérale amyotrophique
MX380889B (es) Lactoferrina para uso en el diagnóstico o el pronóstico de la enfermedad de alzheimer o en el diagnóstico de la enfermedad de parkinson.
MX2021009247A (es) Metodos, sistemas y kits para tratar enfermedades inflamatorias que se dirigen a il18r1.
WO2018038352A3 (fr) Biomarqueur d'auto-anticorps permettant de diagnostiquer la démence et méthode de diagnostic de la démence utilisant celui-ci
MX386075B (es) Metodo y aparato para la prediccion del color postoperatorio de iris percibido
FR3068045B1 (fr) Modeles de peau sensible reconstituee
MX2018011679A (es) Biomarcadores de proteopatias y usos de los mismos.
MX384485B (es) Deteccion temprana de preeclampsia.

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20180629

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7

PLFP Fee payment

Year of fee payment: 8

PLFP Fee payment

Year of fee payment: 9